SMShannon Elizabeth MacDonald

Shannon Elizabeth MacDonald

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shannon Elizabeth MacDonald has a total of 447 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Changes in Post‐Transplant Vaccine Coverage After Implementing Structured Vaccine Reviews in Pediatric Solid Organ Transplant Recipients in British Columbia, Canada: A Canadian Immunization Research Network Study

    by Florence Anne Barbey, Manish Sadarangani, Catherine Burton, Simon Urschel, Shannon E. MacDonald, Athena McConnell, Estelle Morin, Kevin Meesters, Tom Blydt-Hansen, Elaine Yong, et al.

    Background: Children with solid organ transplants (SOT) are at increased risk of infections but may be under‐vaccinated. In 2021, our center implemented structured post‐SOT vaccine reviews. We conducted a single‐center, pre‐post observational study with a repeated cross‐sectional design to assess changes in vaccine coverage from 2020 to 2024. Methods: We performed a chart review of SOT recipients aged 2–18 years who were ≥ 1 year post‐transplant and followed at our clinic on March 1, 2020, and/or March 1, 2024. Patients eligible at both time points (repeat participants) were included in both cohorts; those eligible once (single‐time‐point participants) were included in the respective cohort. We assessed individual and overall vaccine coverage, defined as receipt of all recommended non‐live, non‐seasonal vaccines. Comparisons used the chi‐square and paired McNemar's test (two‐sided p < 0.05). Results: Overall vaccine coverage increased from 33% in 2020 to 51% in 2024. The most prominent changes were observed for 23‐valent pneumococcal polysaccharide (PPV23) and human papillomavirus (HPV) vaccines, with significant improvements among both single‐time‐point (PPV23: 58%–88%, p < 0.001; HPV: 32%–81%, p = 0.003) and repeat participants (PPV23: 52%–76%, p = 0.008; HPV: 20%–53%, p = 0.008). Overall vaccine coverage among patients transplanted at age < 2 years was significantly lower compared to older children in 2020 but not in 2024. Conclusions: Structured post‐transplant vaccine reviews were associated with an increase in coverage across most vaccines and all organ subgroups, supporting its integration into routine post‐transplant care and prospective, multicenter evaluation.

  • Open Access

    What are the current consent processes for adolescent vaccination in Canada? An environmental scan of practices, challenges and alternative approaches

    by Umar Yunusa, Addisu J Zeleke, Laura Reifferscheid, Thilina Bandara, Shannon E MacDonald

    Objectives: Consent processes for adolescent vaccination in Canada have been identified as potential barriers to vaccine uptake. This study examined current practices for obtaining consent for adolescent vaccines across Canadian jurisdictions to better understand the variation, complexity and opportunities for improvement. Design: An environmental scan. Setting: The study was conducted between 25 March 2025 and 27 February 2026, across public health systems in Canada. Data were drawn from relevant written documents and from key informants (KIs) representing public health, vaccine administration and immunisation policy in each province and territory. Participants: We included 76 written records and input from 17 KIs. Primary and secondary outcome measures: The primary outcome was adolescent vaccination consent process, including the age of majority, legal age of consent for vaccination and consent modalities. The secondary outcomes included challenges associated with the existing consent processes and proposed recommendations for improvements. Results: The age of majority was 18 or 19 years in all jurisdictions. The legal age at which adolescents could consent to vaccination ranged from 13 to 16+ years in some jurisdictions, while others did not specify a formal age threshold. Paper-based consent remained the predominant modality, although implied, verbal (in-person) and telephone consent were also used. Electronic consent (e-consent) was being piloted in some jurisdictions. General challenges include logistical burden of paper-based processes and language barriers, whereas adolescent-specific challenges include inconsistent assessment of adolescent capacity and parental concerns about reduced authority. Suggested improvements included simplifying and standardising consent processes, expanding opportunities for adolescent self-consent and integrating e-consents alongside existing modes. Conclusions: Despite considerable variation, there is broad recognition of the need to improve the consent process for adolescent vaccination. Simplifying consent processes may promote more timely and equitable access to immunisation and support efforts to improve adolescent vaccination coverage in Canada.

  • Open Access

    Real-world Impact of HPV Vaccination on CIN2+ Reduction: A Meta-Analysis of Observational Studies Assessing Variation by Age, Coverage, and Vaccine Type

    by Addisu J Zeleke, Laura Reifferscheid, Umar Yunusa, Megan Kennedy, Manish Sadarangani, Gina Ogilvie, Shannon E MacDonald

    Background: Human papillomavirus (HPV) vaccination reduces the incidence of high-grade cervical lesions, but its population-level impact on cervical intraepithelial neoplasia grade 2 or worse (CIN2+) may vary by age at vaccination, program coverage, and vaccine type. The extent to which these factors explain variation in CIN2+ outcomes across real-world vaccination programs remains incompletely quantified. Methods: Using data from a prior systematic review of observational studies across HPV-related endpoints, we restricted this meta-analysis to studies reporting histologically confirmed CIN2+. Reported ratio measures were analyzed on the natural log scale using random-effects models fitted by restricted maximum likelihood with Hartung–Knapp–Sidik–Jonkman inference. Prespecified subgroup analyses examined age at vaccination, vaccination coverage, and vaccine type. Exploratory univariable meta-regressions assessed follow-up duration, age-at-vaccination category, study design, and publication year. Sensitivity analyses evaluated the influence of effect-measure type, alternative between-study variance estimation, and trim-and-fill adjustment. A frequentist network meta-analysis compared vaccine types versus no vaccination. Results: Twenty-two studies were included. HPV vaccination was associated with a pooled ratio estimate of 0.38 (95% CI 0.29–0.50), corresponding to an approximate 62% reduction in CIN2+ occurrence. Heterogeneity was very high (I2 = 97.0%), and the 95% prediction interval crossed 1 (0.12–1.23), indicating substantial variation in expected effects across real-world vaccination programs. Point estimates were generally protective across subgroup strata, but subgroup differences by age at vaccination, vaccination coverage, and vaccine type were not statistically significant. Sensitivity analyses were directionally consistent with the primary analysis. The network meta-analysis suggested lower CIN2+ occurrence for all vaccine-type categories compared with no vaccination; however, all comparisons were indirect through a common no-vaccination comparator, so vaccine-type differences should be interpreted as exploratory. Conclusions: HPV vaccination was associated with a substantial average reduction in CIN2+ occurrence across observational studies. However, high heterogeneity, wide prediction intervals, non-significant subgroup tests, and indirect network comparisons indicate that subgroup and vaccine-type findings should be interpreted cautiously.

  • Open Access

    Vaccination attitudes and intentions reported by Canadian children and their parents in the CHILD Cohort Study during the COVID-19 pandemic

    by Maria V. Medeleanu, Erin E. Gill, Geoffrey L. Winsor, Rilwan Azeez, Larisa C. Lotoski, Stephanie Goguen, Robin M. Humble, Deborah McNeil, David M. Patrick, Shelly Bolotin, et al.

  • Open Access

    Interactive, Personalized Patient Decision Aid for COVID-19 Vaccination in Canada: User-Centered Design Approach

    by Doriane Etienne, Patrick M Archambault, Isaac I Bogoch, Christine T Chambers, Andrea D Chittle, Juliette Demers, S Michelle Driedger, Ève Dubé, Marie-Pierre Gagnon, Teresa Gavaruzzi, et al.

    Background: The COVID-19 pandemic highlighted the need for practical digital health tools to support informed decision-making amid rapidly evolving evidence and widespread misinformation. Objective: We iteratively developed and refined VaxDA-C19, a bilingual (English and French) web-based patient decision aid designed to support informed decision-making in Canada about COVID-19 vaccination. VaxDA-C19 integrates interactive and personalized features aimed to enhance vaccine confidence, reduce cognitive overload, and respond to diverse informational needs. Methods: VaxDA-C19 was developed using an iterative, user-centered design approach. Throughout the development process, we involved a citizen panel, health care professionals, user experience designers, and scientific experts to guide refinements. We also conducted usability testing sessions with adults in Canada, using semistructured interviews, comparative testing, and think-aloud protocols with thematic analysis. We ultimately conducted 4 design cycles in total with adults in Canada (users) and expert reviewers (experts). Cycle 1 involved 9 people (9 users), cycle 2 involved 22 people (22 users), cycle 3 involved 9 people (3 users and 6 experts), and cycle 4 involved 9 people (9 experts). Results: In cycle 1, user feedback guided design decisions about how to present quantitative information and technical vaccine descriptions more simply. In cycle 2, while most users (9/11, 82%) favored in-depth explanations of vaccine development, a few raised concerns about content that could be perceived as politically charged. Cycle 3 identified usability improvements, including more explicit navigation controls, simplified medical terminology, and optimized interactive components (avatars and sliders). Expert reviews in cycle 4 refined linguistic consistency, mobile responsiveness, content transparency, and scientific accuracy, emphasizing explicit instructional guidance and bilingual accessibility. Conclusions: Our iterative process produced a personalized, bilingual digital decision aid to support evidence-informed, values-congruent decisions about COVID-19 vaccination. A randomized controlled trial will further evaluate VaxDA-C19’s impact on vaccination intentions, knowledge retention, emotional responses, decisional conflict, and decisional regret. If it proves effective, the patient decision aid may also be used as a platform to support other vaccine decisions, namely, influenza, measles, shingles, pertussis, and potentially other emerging infectious diseases.

  • Open Access

    An Online Application to Explain Community Immunity with Personalized Avatars: A Randomized Controlled Trial (Preprint)

    by Hina Hakim, Julie A Bettinger, Christine T Chambers, S. Michelle Driedger, Eve Dubé, Teresa Gavaruzzi, Anik Giguere, Noah M Ivers, Anne-Sophie Julien, Shannon E MacDonald, et al.

    BACKGROUND Vaccines protect not only individuals but entire communities through a phenomenon called community immunity (herd immunity). However, understanding this concept can be challenging. OBJECTIVE To evaluate the effects of a web-based, personalized avatar intervention conveying the concept of community immunity on risk perception (perceptions of the risk of infection spreading to self, family, community, vulnerable individuals) and cognitive and emotional responses across 4 vaccine-preventable disease contexts: measles, pertussis, influenza, and an unnamed “vaccine-preventable disease.” METHODS Through user-centered design process, we developed a web application, “herdimm,” showing how community immunity works. In herdimm, people personalize a virtual community by creating avatars (themselves, 2 vulnerable people in their community, and 6 others e.g., family members or co-workers.) Herdimm integrates these avatars in a 2-minute narrated animation showing how infections spread with and without the protection of community immunity. The present study was a 2x4 factorial randomized controlled trial to assess herdimm’s effects. We recruited 3883 adults via Qualtrics in Canada who could complete an online study in English or French. We pre-registered our study on Open Science Framework (https://osf.io/hkysb/). The trial ran from March 1 to July 1, 2021. We compared herdimm to no intervention (control) on primary outcome risk perception, divided into objective (accuracy) and subjective (sense of risk), and on secondary outcomes–emotions (worry, anticipated guilt), knowledge, and vaccination intentions–using analysis of variance for continuous outcomes and logistic regression for dichotomous outcomes. We conducted planned moderation analyses using participants’ scores on a validated scale of individualism and collectivism. RESULTS Overall, herdimm had desirable effects on all outcomes. People randomized to herdimm were more likely to score high on objective risk perception (58.0%, 95% confidence interval 56.0%-59.9%) compared to those assigned to the control condition (38.2%, 95% confidence interval 35.5%-40.9%). Subjective risk perception increased from a mean of 5.30 in the control group to 5.54 in the herdimm group (scale 1–7) The application also increased emotions (F(1,3875)=13.13, p<0.001), knowledge (F(1,3875)=36.37, p<0.001) and vaccination intentions (Chi-squared(1)=9.4136, p=0.002). Objective risk perception did not differ significantly by disease context, but subjective risk perception, emotions, knowledge, and vaccination intentions did. Moderation models showed that many findings were moderated by participants’ individualism and collectivism scores. Overall, whereas outcomes tended not to vary by individualism and collectivism among participants in the control condition, the positive effects of herdimm were larger among participants with more collectivist orientations and effects were sometimes negative among participants with more individualist orientations. CONCLUSIONS Prosocial messaging emphasizing collective vaccination benefits may enhance effectiveness among collectivist audiences but could backfire among individualistic individuals. CLINICALTRIAL ClinicalTrials.gov (NCT04787913) Open Science Framework (https://osf.io/hkysb/)

  • Open Access

    Vaccination policies, practices, and procedures in level-III neonatal intensive care units across Canada: An environmental scan

    by Cassandra Barber, Mikayla Barber, Janet S.W. Lee, Joseph Ting, Shannon E. MacDonald

  • Open Access

    ‘It’s not something that you just do:’ A qualitative analysis of emotion and risk in family decision-making about childhood COVID-19 vaccination

    by Terra A. Manca, Robin Willey, Janet Sau Wun Lee, Emmanuel A. Marfo, Ève Dubé, Shannon E. MacDonald


  • Investigating attributes of stigma towards individuals who did not receive a COVID-19 vaccine: An analysis of user comment threads on Reddit conducted by the Canadian Immunization Research Network (CIRN)

    by Bobbi Rotolo, Natasha Janak Sanghadia, Ève Dubé, James R. Wallace, Janice E. Graham, Christine Huel, Shannon E. MacDonald, Terra Manca, Samantha B. Meyer


  • Open Access

    “This Is Something Every Woman Needs. . .So Why Is It That Expensive?”: Examining Privileges and Inequities in Access to a Privately Funded HPV Vaccination Program in Ghana

    by Emmanuel A. Marfo, Charles A. Adjei, Bukola O. Salami, Shannon E. MacDonald

    The age-standardized incidence and mortality rates for cervical cancer in Ghana is 27.4 and 17.8 per 100,000 women, respectively. Currently, HPV vaccination is available only through privately funded programs, leading to inequitable access and uptake. This study examined how intersecting identities, and social locations contribute to inequities in the privately-funded HPV vaccination program in Ghana. We used an intersectionality-guided qualitative case study design. Data collection included non-participant observation of the clinic context and semi-structured interviews with HPV vaccine recipients ( N = 13). We found that participants’ access to HPV vaccination was shaped by socioeconomic privileges, including the ability to afford the vaccine. Their narratives revealed significant challenges in accessing HPV vaccination and highlighted how intersecting identities contribute to inequities in the privately funded program. Participants reported a general lack of HPV vaccination information in Ghana and often learned about the vaccine through incidental means. Conservative sociocultural norms surrounding sex, sexuality, and reproductive health were significant barriers, particularly in facilitating adolescent-parent discussions about HPV vaccination. Given the inequities reported by vaccine recipients, there is a critical need for education campaigns that raise awareness of the benefits of HPV vaccination, alongside strategies to support socioeconomic empowerment. Addressing these barriers through an inclusive public health policy will help prevent replicating the inequities seen in the privately-funded program and reduce HPV-related diseases, particularly cervical cancer.